+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2019

  • ID: 2563605
  • Report
  • Region: Global
  • 440 Pages
  • CurrentPartnering
1 of 6

FEATURED COMPANIES

  • 3SBio
  • Biogen
  • EpiThany
  • Integral Molecular
  • NeoBiotechnologies
  • Sevion Therapeutics
  • MORE
The Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2019: Deal trends, players, financials and forecasts report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:
  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2014, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading monoclonal antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2014. The chapter is organized by specific monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.

Key benefits

Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2019 provides the reader with the following key benefits:
  • In-depth understanding of monoclonal antibodies deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of monoclonal antibodies agreements with numerous real life case studies
  • Comprehensive access to over 640 actual monoclonal antibodies deals entered into by the world’s biopharma companies
  • Identify the leading monoclonal antibody partnering companies
  • Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope

Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2019 is intended to provide the reader with an in- depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.

Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2019 includes:
  • Trends in monoclonal antibodies dealmaking in the biopharma industry since 2014
  • Analysis of monoclonal antibodies deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 640 monoclonal antibodies deal records
  • The leading monoclonal antibodies deals by value since 2014
  • Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2014
In Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2098, the available deals are listed by:
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Monoclonal antibodies type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2019 report provides comprehensive access to available deals and contract documents for over 640 monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:
  • What are the precise monoclonal antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • 3SBio
  • Biogen
  • EpiThany
  • Integral Molecular
  • NeoBiotechnologies
  • Sevion Therapeutics
  • MORE
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking
2.1. Introduction
2.2. Monoclonal antibody partnering over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody partnering by deal type
2.5. Monoclonal antibody partnering by therapy area
2.6. Deal terms for monoclonal antibody partnering
2.6.1 Monoclonal antibody partnering headline values
2.6.2 Monoclonal antibody deal upfront payments
2.6.3 Monoclonal antibody deal milestone payments
2.6.4 Monoclonal antibody royalty rates

Chapter 3 - Leading monoclonal antibody deals
3.1. Introduction
3.2. Top monoclonal antibody deals by value

Chapter 4 - Most active monoclonal antibody dealmakers
4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody partnering company profiles

Chapter 5 - Monoclonal antibody contracts dealmaking directory
5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory

Chapter 6 - Monoclonal antibody dealmaking by technology type
Monoclonal antibodies
Chimeric mAb
Humanized mAb
Human mAb
Murine mAb

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Monoclonal antibody deals by company A-Z
Appendix 2 - Monoclonal antibody deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Monoclonal antibody deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Appendix 4 - Monoclonal antibody deals by therapy area
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Hematology
Hospital care
Immunology
Infectives
Metabolic
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory
Appendix 5 -Deal type definitions

Table of figures
Figure 1: Therapeutic antibody definitions
Figure 2: Monoclonal antibody partnering since 2014
Figure 3: Active monoclonal antibody dealmaking activity since 2014
Figure 4: Monoclonal antibody partnering by deal type since 2014
Figure 5: Monoclonal antibody partnering by disease type since 2014
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2014
Figure 11: Most active monoclonal antibody dealmakers since 2014
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • 3SBio
  • Biogen
  • EpiThany
  • Integral Molecular
  • NeoBiotechnologies
  • Sevion Therapeutics
  • MORE
Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2019 provides the reader with the following key benefits:
  • In-depth understanding of monoclonal antibodies deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Acces to the structure of monoclonal antibodies agreements with numerous real life case studies
  • Comprehensive access to over 640 actual monoclonal antibodies deals entered into by the world’s biopharma companies, together with real world clause examples
  • Full listing of monoclonal antibodies deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading monoclonal antibodies deals by value since 2014
  • Identify the most active monoclonal antibodies dealmakers since 2014
  • Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Note: Product cover images may vary from those shown
5 of 6
  • 3SBio
  • 4D Pharma
  • Abbvie
  • Abcam
  • AbCellera
  • AbCheck
  • AbClon
  • Ablexis
  • Ablynx
  • Abpro
  • Abzena
  • Acceleron Pharma
  • Accord Healthcare
  • Achaogen
  • Acticor Biotech
  • Actinium Pharmaceuticals
  • Adaptimmune
  • Adaptive Biotechnologies
  • Adimab
  • Adlai Nortye
  • Aduro BioTech
  • Advanced BioScience Laboratories
  • Advantagene
  • Advaxis
  • Aeglea BioTherapeutics
  • Aevi Genomic Medicine
  • AffaMed Therapeutics
  • Affimed Therapeutics
  • Affinita Biotech
  • AGC Biologics
  • Agenus Bio
  • Agilvax
  • Aimmune Therapeutics
  • Alder Biopharmaceuticals
  • Alector
  • Alexion Pharmaceuticals
  • Allergan
  • Alligator Bioscience
  • Almirall
  • Alvogen
  • Ambrx
  • Amgen
  • Amneal Pharmaceuticals
  • AnaptysBio
  • AnGes MG
  • Anthera Pharmaceuticals
  • Antidote Therapeutics
  • Antigen Express
  • Antitope
  • Apceth
  • Apeiron Biologics
  • Aperion Biologics
  • Apexigen
  • Arcus Biosciences
  • arGEN-X
  • argenx
  • Aridis Pharmaceuticals
  • ARMO Biosciences
  • Array Biopharma
  • Arsanis Biosciences
  • Ascenion
  • Ascentage Pharma
  • Aslan Pharma
  • Astellas Pharma
  • Astex Pharmaceuticals
  • AstraZeneca
  • Atara Biotherapeutics
  • Athenex
  • Atlab Pharma
  • AvantGen
  • AVEO Oncology
  • Avid Bioservices
  • Avidity Biosciences
  • Aytu BioScience
  • Back-A-Line
  • Basilea Pharmaceutica
  • Bavarian Nordic
  • Baxalta
  • Bayer
  • Bayer Healthcare
  • Baylor Institute for Immunology Research
  • BB100
  • BeiGene
  • BerGenBio
  • Berkeley Lights
  • Biametrics
  • Bill and Melinda Gates Foundation
  • Bio-Thera Solutions
  • BioArctic Neuroscience
  • BioAtla
  • Biocare Medical
  • Bioceros
  • BiocerOX Products
  • Biodesix
  • BioDuro
  • Biofactura
  • Bio Farma
  • Biogen
  • BioInvent
  • BiolineRX
  • BioMarker Strategies
  • Biomedical Advanced Research and Development Authority
  • Biomunex Pharmaceuticals
  • BioRap Technologies
  • Biothera
  • BioXcel
  • BliNK Biomedical
  • BliNK Therapeutics
  • Boehringer Ingelheim
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • C-Bridge Capital
  • C2N Diagnostics
  • Caliber Biotherapeutics
  • Calithera Biosciences
  • Calypso Biotech
  • Cancer Prevention and Research Institute of Texas
  • Cancer Research Technology
  • Cancer Research UK
  • Catalent Pharma Solutions
  • CBT Pharmaceuticals
  • CDI Laboratories
  • Celexion
  • Celgene
  • Celimmune
  • Celldex Therapeutics
  • Cellectis
  • Cell Marque
  • Cellmid
  • Cell Signaling Technology
  • Celltrion
  • Center for iPS Cells Research and Application
  • Centre for Drug Research and Development (CDRD)
  • Checkmate Pharmaceuticals
  • Chiome Bioscience
  • Chugai Pharmaceutical
  • Cilag AG
  • Cipla
  • City of Hope
  • Clal Biotech
  • Clinica Universidad Navarra
  • Clovis Oncology
  • CMC Biologics
  • Coherus Biosciences
  • Cold Genesys
  • Columbia University
  • Complement Pharma
  • Compugen
  • Conkwest
  • ContraFect
  • Cook Pharmica
  • Corvidia Therapeutics
  • Corvus Pharmaceuticals
  • Covalab
  • Crescendo Biologics
  • Crown Bioscience
  • CR Pharma
  • Crystal Bioscience
  • CSL
  • CSPC Pharmaceutical Group
  • CStone Pharmaceuticals
  • Cullinan Oncology
  • Curant Health
  • CureTech
  • Curie-Cancer
  • Cytodyn
  • CytomX Therapeutics
  • Cytovance Biologics
  • Daiichi Sankyo
  • Dako
  • Debiopharm
  • DecImmune Therapeutics
  • Defense Advanced Research Projects Agency
  • Defyrus
  • Denali Therapeutics
  • DendroCyte
  • Department of Health and Human Services
  • Dermira
  • Distributed Bio
  • DNAtrix
  • Dyadic International
  • Dynavax Technologies
  • EA Pharma
  • Eddingpharm
  • eFFECTOR Therapeutics
  • EirGenix
  • Eisai
  • Eleven Biotherapeutics
  • Eli Lilly
  • ElsaLys Biotech
  • EluSys Therapeutics
  • EMD Millipore
  • EMD Serono
  • Emergent BioSolutions
  • Enthera
  • Enumeral Biomedical
  • Enzo Biochem
  • Epirus Biopharmaceuticals
  • EpiThany
  • Essex Bio-Technology
  • Eureka Therapeutic
  • Eurofarma
  • EUSA Pharma
  • Eutilex
  • Everest Medicines
  • Faron Pharmaceuticals
  • Fate Therapeutics
  • Ferring Pharmaceuticals
  • Five Prime Therapeutics
  • FLX Bio
  • Food and Drug Administration (FDA)
  • Formosa Laboratories
  • Forty Seven
  • Fred Hutchinson Cancer Research Center
  • Fresenius Kabi Pharmaceuticals
  • Fuhong Hanlin
  • Fujifilm Kyowa Kirin Biologics
  • Galapagos
  • Galaxy Biotech
  • Galderma
  • Gallus Biopharmaceuticals
  • GamaMabs Pharma
  • Genagon Therapeutics
  • Genentech
  • GeNeuro
  • Geneva Foundation
  • Genexine
  • Gen Ilac
  • Genmab
  • Genor Biopharma
  • Georgetown University
  • Gilead Sciences
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Global Blood Therapeutics
  • Glycocept
  • Glycotope Biotechnology
  • Glythera
  • Goodwin Biotechnology
  • Gradalis
  • Gritstone Oncology
  • GTP Technology
  • H-Immune
  • H3 Biomedicine
  • Hadasit Bioholdings
  • Halozyme Therapeutics
  • HanAll Pharmaceuticals
  • Harbour Antibodies
  • Harbour Biomed
  • Harvard Pilgrim Health Care
  • Heidelberg Pharma
  • Henlius Biotech
  • Heptares Therapeutics
  • HiFiBio
  • Hikma Pharmaceuticals
  • Hoffmann La Roche
  • Hope Medicine
  • Horizon Discovery
  • Hospira
  • Humabs BioMed
  • Humanigen
  • Hummingbird Bioscience
  • Hutchison MediPharma
  • i2 Pharmaceuticals
  • IBA Molecular Imaging
  • iBio
  • Icahn School of Medicine at Mount Sinai
  • Ichor Medical Systems
  • iDD Biotech
  • Idera Pharmaceuticals
  • Illumina
  • Imab
  • ImaginAb
  • Immatics Biotechnologies
  • Immune Design
  • Immune Pharmaceuticals
  • ImmuNext
  • ImmunoChina Pharmaceuticals
  • Immunocore
  • ImmunoGen
  • Immunomedics
  • Immunomic
  • Immunovaccine
  • Immutep
  • IMPACT Therapeutics
  • Incyte
  • InDevR
  • Infinity Pharmaceuticals
  • Innate Pharma
  • Innovate UK
  • Innovent Biologics
  • Inovio Pharmaceuticals
  • Inserm
  • Inserm Transfert
  • Institut Curie
  • Institute of Biophysics
  • Institut Pasteur
  • Intarcia Therapeutics
  • Integral Molecular
  • International Consortium on Anti-Virals
  • Invenra
  • IO Biotech
  • IONTAS
  • Ipca Laboratories
  • ISA Pharmaceuticals
  • IsoTherapeutics
  • Israel Institute for Biological Research
  • iTeos Therapeutics
  • Izana Bioscience
  • Janssen Biotech
  • Janssen Pharmaceuticals
  • Janssen Research & Development
  • Janssen Sciences
  • Jazz Pharmaceuticals
  • JHL Biotech
  • Jiangsu Hengrui Medicine
  • Johns Hopkins University
  • Johnson & Johnson
  • Johnson & Johnson Innovation
  • Jounce Therapeutics
  • Juno Therapeutics
  • Junshi Biosciences
  • Kadmon Pharmaceuticals
  • Kelun-Biotech Biopharmaceutical
  • Kite Pharma
  • Kodiak Sciences
  • Kolltan Pharmaceuticals
  • Kymab
  • Kyoto University
  • Kyowa Hakko Kirin
  • Laboratoires Thea
  • Laboratorios Liomont
  • LA Cell
  • LakePharma
  • Leaf Biopharmaceutical
  • Leap Therapeutics
  • Lee's Pharmaceutical
  • Leica Biosystems
  • LEO Pharma
  • Les Laboratoires Servier
  • Leukemia & Lymphoma Society
  • LG Life Sciences
  • Libbs Farmaceutica
  • LifeArc
  • Ligand Pharmaceuticals
  • Livzon Mabpharm
  • Lonza
  • Lpath
  • Lupagen
  • Lupin
  • Lupus Therapeutics
  • MAB Discovery
  • Mabion
  • MabQuest
  • Mabspace Bioscience
  • MabVax Therapeutics
  • mAbXience
  • Macquarie University
  • Macrogenics
  • Magenta Therapeutics
  • Mapp Biopharmaceutical
  • Massachusetts General Hospital
  • Mayo Clinic
  • MD Anderson Cancer Center
  • Medgenics
  • Medicago
  • Medigen Biotechnology
  • MedImmune
  • Mediolanum
  • Mediomics
  • Medison Pharma
  • Medivation
  • Memorial Sloan Kettering Cancer Center
  • Merck and Co
  • Merck KGaA
  • Merck Sharpe & Dohme
  • Merrimack Pharmaceuticals
  • Mersana Therapeutics
  • MicroConstants
  • MiniVax
  • Minomic
  • Mitra Biotech
  • Mitsubishi Tanabe Pharma
  • ModiQuest Research
  • Momenta Pharmaceuticals
  • MorphoSys
  • Morphotek
  • Mylan Laboratories
  • Mylan Pharmaceuticals
  • Myriad Genetics
  • NantBioScience
  • NantCell
  • NantKwest
  • Nantong Jinghua Pharmaceutical
  • NantWorks
  • Nanyang Technological University
  • Nascent Biotech
  • National Cancer Institute
  • National Center for Advancing Translational Sciences (NCATS)
  • National Center for Tumor Diseases
  • National Comprehensive Cancer Network (NCCN)
  • National Heart
  • Lung and Blood Institute
  • National Institute for Viral Sidease Control and Prevention
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Standards and Technology
  • National Institutes of Health
  • NCIC Clinical Trials Group
  • Nektar Therapeutics
  • NeoBiotechnologies
  • NeoImmuneTech
  • Neon Therapeutics
  • NeuClone
  • Neurimmune Therapeutics
  • Neuroblastoma and Medulloblastoma Translational Research
  • Newlink Genetics
  • Newsummit Biopharma
  • Nexvet
  • Northern Biologics
  • Northwestern University
  • NovaRock Biotherapeutics
  • Novartis
  • Novasep
  • Novelogics Biotechnology
  • NovImmune
  • Novo Nordisk
  • Noxxon Pharma
  • Numab
  • Ohio Clinical Trials Collaborative
  • Ology Bioservices
  • Olympic Protein Technologies
  • Oncobiologics
  • OncoCare Therapeutics
  • OncoImmune
  • Oncologie
  • Oncolytics Biotech
  • OncoMed Pharmaceuticals
  • OncoQuest
  • OncoSec Medical
  • Oncosynergy
  • Oncothyreon
  • Oncternal Therapeutics
  • Oncurious
  • Ono Pharmaceutical
  • Open Monoclonal Technology
  • Opthea
  • Organic Vaccines
  • OSE Immunotherapeutics
  • Otsuka
  • Oxford BioTherapeutics
  • PacificGMP
  • Pall Corporation
  • Pamlico Biopharma
  • Panacea Pharmaceuticals
  • Pandion Therapeutics
  • PATH Malaria Vaccine Initiative
  • PDS Biotechnology
  • Pelican Therapeutics
  • Peregrine Pharmaceuticals
  • Perelman School of Medicine
  • Personal Genome Diagnostics
  • Pfenex
  • Pfizer
  • PharmAbcine
  • Pharmacyclics
  • PharmaPraxis
  • Pierre Fabre
  • PlantForm
  • Polpharma
  • Portal Instruments
  • Poseida Therapeutics
  • Potenza Therapeutics
  • Precision Biologics
  • Prestige BioPharma
  • Probiodrug AG
  • ProBioGen
  • Progenics Pharmaceuticals
  • Prothena Biosciences
  • ProtoKinetix
  • Provention Bio
  • PULSALYS
  • Purolite
  • Q Therapeutics
  • Quantum Leap Health Care Collaborative
  • Queensland Institute of Medical Research (QIMR)
  • Quest PharmaTech
  • Regeneron Pharmaceuticals
  • Rentschler Biotechnologie
  • Repligen
  • Rexahn Pharmaceuticals
  • Rezolute
  • Ridgeback Biotherapeutics
  • River Vision Development
  • Roche
  • Rockefeller University
  • Rockland Immunochemicals
  • Roivant Sciences
  • Roswell Park Cancer Institute
  • RuiYi
  • SAB Therapeutics
  • Samsung Bioepis
  • Samsung Biologics
  • San Diego Biomedical Research Institute
  • Sanofi
  • Sanofi-Aventis
  • Sanofi-Pasteur
  • Sarah Cannon Research Institute
  • SATT Sud-Est
  • Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO)
  • Schrodinger
  • Sea Lane Biotechnologies
  • Seattle Genetics
  • Selexis
  • SELLAS Life Sciences Group
  • Serum Institute of India
  • Sevion Therapeutics
  • ShanghaiTech University
  • Shenzhen Arimab Biopharmaceuticals
  • Shenzhen Chipscreen Biosciences
  • Shenzhen Hepalink Pharmaceutical
  • Shire Pharmaceuticals
  • Simon Fraser University
  • Small Business Innovation Research
  • Solentim
  • Sorrento Therapeutics
  • Stanford University
  • Strata Oncology
  • Strox Biopharmaceuticals
  • Sun Pharmaceutical
  • Surface Oncology
  • Swedish Orphan
  • Swedish Orphan Biovitrum
  • Symphogen
  • Syndax Pharmaceuticals
  • Syros Pharmaceuticals
  • Taiho
  • TaiMed
  • Taiwan Ministry of Economic Affairs
  • Takeda Pharmaceutical
  • Tanabe Research Laboratories
  • TARIS Biomedical
  • Telix Pharmaceuticals
  • TeneoBio
  • Tesaro
  • Tessa Therapeutics
  • Tetragenetics
  • TetraLogic Pharmaceuticals
  • Teva Pharmaceutical Industries
  • TG Therapeutics
  • Theradiag
  • Theranyx
  • Theravectys
  • ThromboGenics
  • Tikcro Technologies
  • Tiziana Life Sciences
  • Tizona Therapeutics
  • Tmunity Therapeutics
  • Torque Therapeutics
  • TOT BIOPHARM
  • TRACON Pharmaceuticals
  • TransBio
  • Transcenta
  • Transgene
  • TransPerfect Life Sciences
  • Transporin
  • Trellis Bioscience
  • Tri-Institutional Therapeutics Discovery Institute
  • Trianni
  • Trieza Therapeutics
  • Turgut Ilaclari
  • UCB
  • UMass Memorial Medical Center
  • Unilife
  • Universite Claude Bernard Lyon
  • University College London
  • University of British Columbia
  • University of California
  • San Diego
  • University of California Los Angeles
  • University of California San Francisco
  • University of Cologne
  • University of Illinois at Chicago
  • University of Maryland Baltimore
  • University of Massachusetts Medical School
  • University of Minnesota
  • University of Nottingham
  • University of Pennsylvania
  • University of Rochester
  • University of Texas
  • University of Wisconsin Carbone Cancer Center (UWCCC)
  • Unum Therapeutics
  • Uppsala University
  • US Government
  • Utrecht University
  • Vaccinex
  • Valeant Pharmaceuticals
  • Valneva
  • Vaximm
  • Vect-Horus
  • Vedanta Biosciences
  • Ventana Medical Systems
  • Verastem
  • Verseau Therapeutics
  • VIB
  • Vical
  • Viela Bio
  • Vinnova
  • Viralytics
  • Virbac
  • Vir Biotechnology
  • Visterra
  • Vitaeris
  • Voyager Therapeutics
  • Vyriad
  • Wilex
  • Wistar Institute
  • World Health Organization
  • WuXi Biologics
  • XBiotech
  • Xbrane Bioscience
  • xCella Biosciences
  • Xencor
  • Xoma
  • Yale University
  • Yeda Research and Development Company
  • Yissum Research Development
  • YL Biologics
  • Yoshindo
  • ZAI Laboratory
  • Zenoaq
  • Zenyaku Kogyo
  • Zhejiang Bossan Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceutical
  • Zoetis
  • Zymeworks
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/2563605
Adroll
adroll